Immune Checkpoint Inhibition in Oesophago-Gastric Carcinoma

Immune Checkpoint Inhibition in Oesophago-Gastric Carcinoma

Immune checkpoint inhibitors enrich the therapeutic landscape in oesophago-gastric carcinoma. With regard to oesophageal squamous cell carcinoma (ESCC), the selective PD-1 (programmed cell death receptor 1)-inhibitor nivolumab improves disease-free survival in the adjuvant therapy setting (CHECKMATE...

Full description

Bibliographic Details
Main Authors: Anica Högner, Peter Thuss-Patience
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Pharmaceuticals
Subjects:
gastrointestinal cancer
oesophageal cancer
stomach cancer
immune checkpoint inhibitors
programmed death receptor
nivolumab
Online Access:https://www.mdpi.com/1424-8247/14/2/151

Internet

https://www.mdpi.com/1424-8247/14/2/151

Similar Items